Linea Directa Aseguradora SA Compania de Seguros y Reaseguros (LDA)
Madrid Exchange · Spain · prices in EUR · close of 22 Oct 2026
Key indicators
| Last close | EUR 1.234 |
|---|---|
| 52-week range | 1.066 – 1.360 |
| Return, 1 month / 3 months | −4.3% / −1.3% |
| Return, 1 year / 3 years | −0.1% / +55.3% |
| Trend | Above 200-day, below 50-day |
| RSI (14) | 46 |
| Volatility (1 year) | 21.8% |
| Worst drawdown (1 year) | -11.9% |
| Average daily value traded | 0.65M EUR |
| Dividend yield | 3.6% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Linea Directa Aseguradora is a Spanish insurance company that sells policies directly to customers rather than through agents or brokers. It is based in Spain and its main business is motor insurance, alongside home, life and health cover for individuals and families. The company handles its own claims and customer service, and it markets its products under the Linea Directa brand to households across the country.
The shares are listed on the Madrid Exchange in Spain under the code LDA, and the price on this page is in euros (EUR). Our dividend records, which start in 2019, show payments in 6 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Linea Directa Aseguradora SA Compania de Seguros y Reaseguros (LDA) trades on the Madrid Exchange in Spain. It last closed at EUR 1.234 on 22 October 2026.
Its price-based Market X-Ray is 67 out of 100 (a fair price profile), ranking 42 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 0.1% and over the last three months it fell 1.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 72 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 2.3% | ||
| From 52-week high | -9.1% | ||
| Momentum | 58 · Fair | Typical recent returns for this exchange. | |
| 3-month return | -1.3% | ||
| 6-month return | 0.6% | ||
| 12-month return, skipping the last month | 4.4% | ||
| Stability (higher is calmer) | 65 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 21.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -11.9% | ||
| Liquidity | 73 · Strong | Trades actively. | |
| Average daily value traded | 0.65M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 73 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 3.6% | ||
| Years with dividends | 6 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −0.2% |
|---|---|
| 1 month | −4.3% |
| 3 months | −1.3% |
| 6 months | +0.6% |
| 1 year | −0.1% |
| 3 years | +55.3% |
| 5 years | −15.6% |
Signals
| 50-day / 200-day average | 1.281 / 1.206 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.022 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 3 Jul 2026 | EUR 0.0166 |
| 20 Apr 2026 | EUR 0.0138 |
| 3 Dec 2025 | EUR 0.0138 |
| 27 Jun 2025 | EUR 0.0138 |
| 15 Apr 2025 | EUR 0.0138 |
| 17 Dec 2024 | EUR 0.0138 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.